Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
Agios Pharmaceuticals Inc. (NASDAQ: AGIO) shares surged 26.20 percent to close at $39.93 a share Thursday. The stock traded between $30.51 and $42.92 on volume of 1.12 million shares traded. The company reported collaboration revenue was $6.7 million for the fourth quarter of 2013, compared to $6.3 million a year ago. Shares of Agios Pharmaceuticals are up approximately 66.0 percent year-to-date.
Get more information on Agios Pharmaceuticals and free access to the in-depth equity report at: www.FiveStarEquities.com/AGIO
Pixelworks, Inc. (NASDAQ: PXLW) shares soared 87.50 percent to close at $9.00 a share Thursday. The stock traded between $6.31 and $9.05 on volume 30.92 million shares traded. The company recently disclosed that Apple Inc. accounted for approximately 10.0 percent of its revenues in 2013. Shares of Pixelworks are up approximately 85.0 percent year-to-date.
Get more information on Pixelworks and free access to the in-depth equity report at: www.FiveStarEquities.com/PXLW
Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR) shares increased 5.38 percent to close at $26.26 a share Thursday. The stock traded between $25.24 and $28.50 on volume of 1.08 million shares traded. The company announced that the FDA has granted Fast Track designation for the development of TKM-Ebola, an anti-Ebola viral therapeutic. Shares of Tekmira Pharmaceuticals are up approximately 230.0 percent year-to-date.
Get more information on Tekmira Pharmaceuticals and free access to the in-depth equity report at: www.FiveStarEquities.com/TKMR
WuXi PharmaTech (Cayman) Inc. (NYSE: WX) shares dropped 8.23 percent to close at $36.13 a share Thursday. The stock traded between $35.20 and $37.74 on volume 2.30 million shares traded. The company’s first quarter guidance of revenues in the range of $143 million to $145 million fell short of expectations. Shares of WuXi PharmaTech are down approximately 6.0 percent year-to-date.
Get more information on Zumiez free access to the in-depth equity report at: www.FiveStarEquities.com/WX
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Contact: Five Star Equities [email protected]